FDA panel backs Amgen's biosimilar Humira

FDA's Arthritis Advisory Committee voted unanimously Tuesday to recommend approval of ABP 501 from Amgen

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE